Nkarta surges on promising early data from cell therapies

Nkarta

25/04/2022 12:17

** Cell therapy developer's shares  NKTX.O  jump 50.6% to
$11.79 premarket 
    ** Co says two of its experimental cell therapy treatments
showed promise in patients with different blood disorders
 urn:newsml:reuters.com:*:nGNX4V9ZHz
    ** NKTX says both drugs, NKX101 and NKX019, were well
tolerated, with no reports of side effects that are associated
with CAR-T cell therapies, such as cytokine release syndrome or
graft versus host disease
    ** NKTX has lost nearly half its value this year 

 (Reporting by Manas Mishra)
 ((Manas.Mishra@thomsonreuters.com;
www.twitter.com/Manaswrites15))